Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 21

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 21
---
 alliances.

Between 2020 and 2023, we raised aggregate gross
proceeds of $8.15 million, from sales of our equity and equity linked securities. Nonetheless, we will need to obtain substantial additional
funding for the further development and commercialization of our product candidates and to continue our operations. The actual amount
of funds that we will need will be determined by many factors, some of which are beyond our control. These factors include:

| ● | The progress and breadth                                                                                                              
 of pre-clinical testing and the size or complexity of our clinical trials and drug delivery programs, all of which directly influence 
 cost;                                                                                                                                 |

| ● | Higher than expected costs                                                                                                       
 involved in complying with the regulatory process to get our drug candidates approved, including the number, size, and timing of 
 necessary clinical trials and costs and review of existing clinical and pre-clinical information;                                |

| ● | Higher than expected costs                                                                                         
 involved in patenting our technologies and defending them and pursuing our overall intellectual property strategy. |

<div align='center'>9</div>

| ● | Changes in our existing                                                                                                          
 research and development relationships and our ability to efficiently negotiate and enter into new collaboration and partnership 
 agreements.                                                                                                                      |

| ● | Our ability to establish                                                                                                            
 and maintain current and new research and development and licensing arrangements and terminations of our existing collaboration and 
 licensing arrangements.                                                                                                             |

| ● | Faster or slower than expected                                                                                        
 rate of progress and changes in the scope and the cost of our research and development and clinical trial activities. |

| ● | Higher than expected costs                                                                                                       
 of preparing an application for clinical trials and FDA and similar regulatory authorities’ approvals of our product candidates’ 
 development programs.                                                                                                            |

| ● | FDA approval in general. |

| ● | Higher than expected costs                                                                                                        
 to further develop and scale up manufacturing of our therapeutic candidates through CDMOs (Contract Development and Manufacturing 
 Organizations).                                                                                                                   |

| ● | Competition for our products. |

| ● | Our ability to achieve                                                                                                                 
 milestones under licensing arrangements and the costs involved in enforcing or defending patent claims and other intellectual property 
 rights.                                                                                                                                |

To date, we have financed our operations through
a mix of equity investments from private investors, and we expect to continue to utilize such means of financing for the foreseeable
future. However, additional funding from those or other sources may not be available when or in the amounts needed, on acceptable terms,
or at all.

If